These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 35983168

  • 1. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England.
    Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1781-1795. PubMed ID: 35983168
    [Abstract] [Full Text] [Related]

  • 2. Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England.
    Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023; 18():231-245. PubMed ID: 36908830
    [Abstract] [Full Text] [Related]

  • 3. Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β2-agonist dual therapy in a primary care setting in England.
    Czira A, Banks V, Requena G, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS.
    BMJ Open Respir Res; 2022 Sep; 9(1):. PubMed ID: 36171051
    [Abstract] [Full Text] [Related]

  • 4. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England.
    Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Sep; 18():643-659. PubMed ID: 37155496
    [Abstract] [Full Text] [Related]

  • 5. Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study.
    Czira A, Banks V, Requena G, Wood R, Tritton T, Wild R, Compton C, Ismaila A.
    BMJ Open; 2024 Feb 07; 14(2):e072361. PubMed ID: 38326272
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.
    Adv Ther; 2020 Jun 07; 37(6):2956-2975. PubMed ID: 32335859
    [Abstract] [Full Text] [Related]

  • 7. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
    Rothnie KJ, Joksaite S, Sansbury LB, Compton C, Di Boscio V, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2022 Jun 07; 17():1455-1466. PubMed ID: 35769225
    [Abstract] [Full Text] [Related]

  • 8. Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.
    Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E.
    Int J Chron Obstruct Pulmon Dis; 2022 Jun 07; 17():1715-1733. PubMed ID: 35941901
    [Abstract] [Full Text] [Related]

  • 9. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo C, Yeap J, Wild R, Compton C, Rothnie KJ, Herth FJF, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Jun 07; 18():2039-2054. PubMed ID: 37731774
    [Abstract] [Full Text] [Related]

  • 10. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
    Beeh KM, Rothnie KJ, Claussen J, Hardtstock F, Knapp RK, Wilke T, Czira A, Compton C, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2024 Jun 07; 19():945-956. PubMed ID: 38646606
    [Abstract] [Full Text] [Related]

  • 11. Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database.
    Milea D, Yeo SH, Nam Y, Navarro Rojas AA, Shantakumar S, Beale J, Marett B, Young RP, Scott RJ, Gribben B.
    Int J Chron Obstruct Pulmon Dis; 2021 Jun 07; 16():1075-1091. PubMed ID: 33907394
    [Abstract] [Full Text] [Related]

  • 12. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
    Feldman WB, Avorn J, Kesselheim AS, Gagne JJ.
    JAMA Intern Med; 2023 Jul 01; 183(7):685-695. PubMed ID: 37213116
    [Abstract] [Full Text] [Related]

  • 13. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
    J Manag Care Spec Pharm; 2021 Jul 01; 27(7):810-824. PubMed ID: 33764161
    [Abstract] [Full Text] [Related]

  • 14. Long-acting muscarinic antagonist and long-acting β2-agonist combination for the treatment of maintenance therapy-naïve patients with chronic obstructive pulmonary disease: a narrative review.
    Buhl R, Miravitlles M, Anzueto A, Brunton S.
    Ther Adv Respir Dis; 2024 Jul 01; 18():17534666241279115. PubMed ID: 39352722
    [Abstract] [Full Text] [Related]

  • 15. Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice.
    Ding B, Kallenbach L, Slipski L, Wilk A, O'Brien D, Guranlioglu D.
    Int J Chron Obstruct Pulmon Dis; 2020 Jul 01; 15():775-786. PubMed ID: 32346288
    [Abstract] [Full Text] [Related]

  • 16. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
    Liao PA, Pan SW, Chen CY, Deng CY, Dong YH.
    Int J Chron Obstruct Pulmon Dis; 2023 Jul 01; 18():553-563. PubMed ID: 37069844
    [Abstract] [Full Text] [Related]

  • 17. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
    Lane DC, Stemkowski S, Stanford RH, Tao Z.
    J Manag Care Spec Pharm; 2018 Nov 01; 24(11):1165-1172. PubMed ID: 30362922
    [Abstract] [Full Text] [Related]

  • 18. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
    Bloom CI, Elkin SL, Quint JK.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 01; 14():279-287. PubMed ID: 30774325
    [Abstract] [Full Text] [Related]

  • 19. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
    Heo YA.
    Drugs; 2021 Aug 01; 81(12):1411-1422. PubMed ID: 34342835
    [Abstract] [Full Text] [Related]

  • 20. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr 01; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.